ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non-muscle-invasive bladder cancer.

ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non-muscle-invasive bladder cancer. Meeting Abstract

publication date

February 10, 2025

webpage

Web of Science

published in

JOURNAL OF CLINICAL ONCOLOGY Journal

start page

TPS888

end page

TPS888

volume

43

issue

5_SUPPL